Company: SUPN
Filing Date: 2025-02-25
Form Type: 10-K
Source: 0001356576-25-000017
Chunk: 43

Company: SUPERNUS PHARMACEUTICALS, INC.
Filing Date: 2025-02-25
Form: 10-K
Item: Item 1C
Chunk 43
---
2,769 60,743 Income tax expense24,005 1,453 32 Net earnings$73,865 $1,316 $60,711 Earnings per shareBasic$1.34 $0.02 $1.13 Diluted$1.32 $0.02 $1.04 Weighted average shares outstandingBasic55,100,063 54,536,281 53,665,143 Diluted55,958,537 55,506,828 61,679,800 

(a) Excludes amortization of intangible assets.

See accompanying notes.

93

Supernus Pharmaceuticals, Inc.

Consolidated Statements of Comprehensive Earnings

(in thousands) Year Ended December 31, 202420232022Net earnings$73,865 $1,316 $60,711 Other comprehensive gain (loss)Unrealized gain (loss) on marketable securities, net of tax404 2,617 (4,749)Other comprehensive gain (loss)404 2,617 (4,749)Comprehensive earnings$74,269 $3,933 $55,962 

See accompanying notes.

94

Supernus Pharmaceuticals, Inc.

Consolidated Statements of Changes in Stockholders' Equity

(in thousands, except share data)Common StockAdditionalPaid-inCapitalAccumulatedOtherComprehensiveEarnings (Loss)RetainedEarningsTotalStockholders'Equity SharesAmountBalance, December 31, 202153,256,094 $53 $434,337 $1,539 $379,922 $815,851 Cumulative effect of adoption of ASU 2020-06— — (56,212)— 40,612 (15,600)Balance, January 1, 202253,256,094 53 378,125 1,539 420,534 800,251 Share-based compensation expense related to employee stock purchase plan and share-based awards— — 17,568 — — 17,568 Issuance of common stock related to employee stock purchase plan and share-based awards997,702 1 12,422 — — 12,423 Net earnings— — — — 60,711 60,711 Unrealized loss on marketable securities, net